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Abstract
Background: Surgical procedures such as liver resection and liver transplantation are the first-line treatments for
hepatocellular carcinoma (HCC) patients. However, the high incidence of tumor recurrence and metastasis after liver surgery
remains a major problem. Recent studies have shown that hepatic ischemia-reperfusion (I/R) injury and endothelial
progenitor cells (EPCs) contribute to tumor growth and metastasis. We aim to investigate the mechanism of FTY720, which
was originally applied as an immunomodulator, on suppression of liver tumor metastasis after liver resection and partial
hepatic I/R injury.
Methodology/Principal Findings: An orthotopic liver tumor model in Buffalo rat was established using the hepatocellular
carcinoma cell line McA-RH7777. Two weeks after orthotopic liver tumor implantation, the rats underwent liver resection for
tumor-bearing lobe and partial hepatic I/R injury. FTY720 (2 mg/kg) was administered through the inferior caval vein before
and after I/R injury. Blood samples were taken at days 0, 1, 3, 7, 14, 21 and 28 for detection of circulating EPCs
(CD133+CD34+). Our results showed that intrahepatic and lung metastases were significantly inhibited together with less
tumor angiogenesis by FTY720 treatment. The number of circulating EPCs was also significantly decreased by FTY720
treatment from day 7 to day 28. Hepatic gene expressions of CXCL10, VEGF, CXCR3, CXCR4 induced by hepatic I/R injury
were down-regulated in the treatment group.
Conclusions/Significance: FTY720 suppressed liver tumor metastasis after liver resection marred by hepatic I/R injury in a
rat liver tumor model by attenuating hepatic I/R injury and reducing circulating EPCs.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignancies in the world [1]. Surgical procedures such as liver
resection and liver transplantation are the first-line treatments for
HCC patients. However, the high incidence of tumor recurrence
and metastasis after liver surgery remains a major problem [2,3].
Therefore, it is a pressing need to develop novel therapies to
eliminate tumor recurrence and metastasis after liver surgery.
Surgical stress injury such as hepatic ischemia reperfusion (I/R)
injury is an inevitable consequence during liver surgery. Hepatic
I/R injury promote liver tumor growth and metastases through
activation of cell adhesion, invasion, and angiogenesis pathways
[2–4]. Furthermore, accumulating evidence indicated that surgical
stress injury can rapidly increase the number of circulating EPC
[5–7]. These events are also associated with elevated levels of
vascular endothelial growth factor (VEGF), stem cell factor (SCF),
and granulocyte colony-stimulating factor (G-CSF) that stimulate
the release of EPCs from the bone marrow [5,8–10].
EPCs, a subtype of progenitor cells in postnatal bone marrow,
have the capacity to migrate to the peripheral circulation and
differentiate into mature endothelial cells [11,12]. Several
researches have showed that circulating level of EPCs is higher
in patients with advanced HCC, which may act as a potential
prognostic marker in HCC patients [13,14]. Furthermore, EPCs
play important roles in tumor vasculogenesis and tumor growth at
early phase by providing structural support to nascent vessels and
the release of pro-angiogenic cytokines [10,15–17]. EPCs have
major roles in the tumor progression from micrometastases to
macrometastases [18].
FTY720, is synthetically derived from myriocin (ISP-1), a
metabolite isolated from ascomycete, Isaria sinclarii [19]. FTY720
has been demonstrated to attenuate hepatic I/R injury by
ameliorating acute phase inflammatory response and up-regulat-
ing several protective genes including heat shock proteins and anti-
apoptotic genes [20,21]. Recently several groups have shown that
FTY720 has a strong antitumor effect on liver cancer, breast
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our hypothesis was that FTY720 may suppress liver tumor
metastasis after liver surgery through attenuating hepatic I/R
injury and subsequently reducing circulating EPCs.
In this study, we aimed to investigate whether FTY720
suppresses liver tumor metastasis after liver tumor resection and
partial hepatic I/R injury by attenuating hepatic I/R injury and
reducing circulating EPCs level in an orthotopic rat liver tumor
model. The significance of this study will hopefully open a novel
therapy to reduce liver tumor metastasis after liver surgery for
HCC patients.
Materials and Methods
Animal Model
Buffalo rat hepatoma cell line McA-RH7777 (1610
6/100 ul)
(Purchased from the American Type Culture Collection, Number
CRL1601, ATCC, Manassas, VA, USA) labeled with luciferase
[26], was injected into hepatic capsule of buffalo rat to induce solid
tumor. When the size of tumor volume reached 10610 mm
(length6width) in size, tumor tissues were harvested and cut into
1–2 mm
3 cubes and implanted into the left liver lobes of a new
group of buffalo rats. Two weeks after orthotopic liver tumor
implantation, the orthotopic liver tumor reached around 1 cm in
diameter. The right branch of portal vein and hepatic artery were
clamped for 30 minutes by micro vessel clamp and released
afterwards. The left lobe of the liver was removed after cross
clamping of the portal vein. Rats were housed in a standard
animal laboratory with free activity and access to water and food.
They were kept under constant environment conditions with a 12-
hour light-dark cycle. All operations were performed under clean
conditions. The study had been licensed according to Animal
Ordinance Chapter 340 by the Department of Health, Hong
Kong Special Administrative Region (ref.: (08-64) in DH/HA&P/
8/2/3 Pt. 3).
Treatment Regimen, Imaging Analysis, and Sample
Collection
FTY720 (2 mg/kg, diluted with saline water, treatment group)
or saline water (control group) were administrated through the
inferior caval vein before and after I/R injury. Both the treatment
group and the control group comprised 22 rats each. Six rats in
each group were sacrificed at 6 h after reperfusion to study the
role of FTY720 in attenuate hepatic I/R injury and expressions of
some inflammatory cytokines and chemokines. Remaining Buffalo
rats were used to monitor tumor metastasis after hepatectomy and
hepatic I/R injury by the Xenogen in vivo imaging system through
detection of luminance signals from tumor cells [27]. Blood
samples were collected at days 0 (before liver resection and I/R
injury), 1, 3, 7, 14, 21 and 28 from tail vein for detection of
circulating EPCs. And then Buffalo rats were sacrificed at 4 weeks
after liver resection and I/R injury. Liver, lung, kidney, and spleen
suspected of tumor metastasis were sampled for further investiga-
tion. Furthermore, rat bone-marrow was also collected from rat
femurs for detecting the number of EPCs.
Detection of Circulating and Bone Marrow EPCs by Flow
Cytometry
Rat peripheral blood mononuclear cells (PBMCs) were isolated
after lysis red blood cells with a 16 ACK lysis buffer(NH4Cl
8.29 g/l,KHCO3 1 g/l,Na2-EDTA 37.2 mg/l). PBMCs were
recovered by spinning at 1000 rpm for 5 minutes and were
washed extensively with PBS containing 1% BSA. Cells were re-
suspended in PBS-1% BSA, counted, and recovered by centrifu-
gation. For analysis of EPCs surface molecules, cells were stained
with the following antibodies: unconjugated rabbit anti-CD133
(Abcam, Cambridge, UK), PE-conjugated anti-CD34 (Santa Cruz
Biotech, Santa Cruz, CA), PE-Cy5-conjugated anti-CD45 (BD
Pharmingen, San Diego, CA) and goat anti-rabbit FITC
secondary antibody (Abcam, Cambridge, UK). Corresponding
isotype-matched control monoclonal antibodies were used in all
flow cytometric staining procedures. Flow cytometric analysis was
performed using a FACSCalibur (Becton Dickinson, San Diego,
CA).
Hematoxylin and Eosin (H & E) and
Immunohistochemical (IHC) Staining
The samples were fixed in 10% formalin and embedded in
paraffin. Paraffin sections (4 mm thick) were dewaxed in xylene,
rinsed in grade alcohol, and rehydrated in water and then was
stained with H&E for histological examination. The expression of
CD34 (Santa Cruz Biotechnology) was detected by immunohis-
tochemical staining [27]. The first step was the same as the H&E
staining, and then the paraffin sections placed in citric buffer
(pH 6.0) and treated in a microwave. Afterwards, the sections
underwent blocking with 10% FBS for 30 min. Subsequently,
primary antibodies with proper dilution were applied on the
sections, which were then incubated at 4uC overnight. Then the
sections underwent blocking with 3% peroxidase for 30 min and
following that, secondary antibodies from Dako EnVision System
(DakoCytomation) were applied, and the sections were incubated
for 30 min at room temperature. Signals were developed with
3,39-diaminobenzidine substrate solution (DakoCytomation). The
sections were finally counterstained by hematoxylin solution.
Determination of microvessel density and Tumor Load
Analyses
Microvessel density (MVD) of liver tumor tissue sections was
evaluated [27,28]. Any CD34+ stained endothelial cell or
endothelial cell cluster that was clearly separated from adjacent
microvessels, tumor cells, and connective elements was counted as
one microvessel. The mean microvessel count of the six most
vascular areas was taken as the MVD, which was expressed as the
absolute number of microvessels per 1.485 mm2 (6200 field).
Intrahepatic tumor load was scored as the percentage of hepatic
replacement area (HRA) by tumor in liver based on 4
nonsequential hematoxylin-eosin staining sections by an integrated
imaging system [29]. The number of lung metastasis tumor
nodules was also counted.
Detection of Hepatic Apoptosis by TUNEL Staining
TUNEL assay was performed to detect the apoptotic nuclei in
paraffin sections, by using in situ Cell Death Detection Kit, POD
(Roche Applied Science, Mannheim, Germany) [21].
Assessment of Hepatic Gene Expression Profiles
Liver tumor tissue was stored at 280uC until total RNA
extraction. Total RNA was extracted using RNeasy Midi kit
(Qiagen). Total RNA (1 mg) from each sample was used to perform
reverse transcription reaction using high capacity cDNA Kit
(Applied Biosystems). Reverse transcription product (1 ml) was
used to perform real-time quantitative reverse transcription-PCR
by ABI PRISM 7700 Sequence Detection System (Applied
Biosystems). Amplification of 18 S ribosomal RNA was applied
as the internal control. Readings from each sample and its internal
control were used to calculate gene expression level. After
normalization with the internal control, gene expression levels
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sequences of the primers were listed as follows: VEGF: Left
AAATGCTTTCTCCGCTCTGA, Right TTCCTGCAGCAT-
AGCAGATG; IP10: Left TTCCAATCCCAGCTACATC, Right
ACTCAGACTCAGCAGCAC; CXCR3: Left AGCACAGAC-
ACCTTCCTGCT, Right CAGAGACCAGAGCCGAAAAC;
CXCR4: Left CTCCAAGCTGTCACACTCCA, Right GAT-
GCTGATCCCCACGTAAT.
Protein expression of ROCK, IP10, VEGF
Western blot was done with a modified version of a method
described previously [30]. Anti-CXCL10, anti-VEGF, anti-
CXCR3 and anti-CXCR4 antibodies were purchased from Santa
Cruz Biotechnology.
Statistics and Data Analyses
Continuous variables were expressed as median with range.
Mann-Whitney U test was used for statistical comparison. x
2 test
was used to compare incidence of intrahepatic and lung metastasis
after hepatectomy and I/R injury. P,0.05 was considered
statistically significant. Calculations were performed by using the
SPSS computer software version 15 (SPSS, Chicago, IL).
Results
FTY720 suppressed liver tumor metastasis after major
hepatectomy and partial hepatic I/R injury
In order to investigate the effect of FTY720 on the metastasis of
liver tumor afterhepatectomy and partialI/Rinjury, we established
a rat orthotopic liver tumor model with local and distant metastatic
potentials (Figure 1A). Before the major hepatectomy and partial I/
R injury, the average size of liver tumor did not show significant
difference between the treatment and control group; the mean
diameters of the tumors were 1.160.3 cm and 1.060.3 cm,
respectively. The result showed that, after FTY720 treatment, the
incidence of intrahepatic metastasis decreased from 68.75% (11 of
16) to 37.5% (6 of 16; P=0.07) (Table 1). Similarly, there was an
inhibition of lung metastasis by FTY720 treatment, manifested by a
drop of incidence from 56.25% (9 of 16) to 31.25% (5 of 16;
P=0.15) (Table 1). More importantly, the number of metastatic
tumor nodules in lung and metastatic tumor size in liver were
significantly reduced by FTY720 treatment (Table 1). Intrahepatic
and lung metastasis were detected by the Xenogen in vivo imaging
system and further confirmed by histology examination (Figure 1B,
C). Tumor metastasis was not found in other organs in both
treatment and control group.
FTY720 significantly reduced circulating and bone
marrow EPCs
In order to explore the underlying mechanism of FTY720 on
suppressing tumor metastasis, we examined the population of the
Figure 1. FTY720 suppressed liver tumor intrahepatic and lung metastasis after hepatectomy and I/R injury. (A) Orthotopic liver tumor
model with metastatic potentials was established in buffalo rats. (B) intrahepatic and Lung metastasis were detected by Xenogen imaging and
confirmed in specimen at four weeks after liver resection and I/R injury. (C) Histological features of liver tumors from buffalo rats at four weeks after
hepatectomy and partial I/R injury with and without FTY720 treatment.
doi:10.1371/journal.pone.0032380.g001
Table 1. Comparison of tumor metastasis after liver resection
and I/R injury.
Control
group
Treatment
group P value
Intrahepatic metastasis
Metastasis ratio 11/16 (68.75%) 6/16(37.5%) 0.07
HRA(% tumor in liver) 33.84% (15–45.6%) 19.11% (4.4–22.6%) 0.006
Lung metastasis
Metastasis ratio 9/16 (56.25%) 5/16 (31.25%) 0.15
Number(tumor
nodules)/rat
8.4(3–20) 3.6 (1–8) 0.046
Note: average (range).
doi:10.1371/journal.pone.0032380.t001
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I/R injury. Before the major hepatectomy and partial I/R injury,
the number of circulating EPCs did not show notable difference
between the treatment group and control group (Figure 2A). The
number of circulating EPCs was reduced at day 1and day 3 after
the major hepatectomy and partial I/R injury in both groups.
For both treatment and control groups, the level of circulating
EPCs was higher in the rats with metastasis than without
metastasis. The average level of circulating EPCs was significantly
decreased by FTY720 treatment from day 7 to day 28 (day7: 54
vs 295/10
5 PBMC cells, P=0.001;d a y 1 4 :4 6vs 607/10
5 PBMC
cells, P=0.000;d a y 2 1 :4 8vs 672/10
5 PBMC cells, P=0.000;
day28: 124 vs 2345/10
5 PBMC cells, P=0.000) (Figure 3A).
Furthermore, at four weeks after liver resection and I/R injury,
the number of EPCs in bone-marrow in treatment group was also
less than the control group (22.5 vs 83.6/10
5 Cells, P=0.000)
(Figure 2B).
FTY720 decreased the MVD in metastatic tumor nodules
We analyzed the expression of CD34 in intrahepatic and lung
metastatic tumor nodules by IHC staining. At four weeks after
tumor resection and I/R injury, immunostaining revealed a large
number of CD34 positive cells in intrahepatic and lung metastatic
tumor nodules in the control group. On the contrary, only a few
number of CD34 positive cells were detected in the treatment
group (Figure 3A). Furthermore, MVD was also decreased in both
intrahepatic and lung metastatic tumor nodules after FTY720
treatment (Figure 3B).
Figure 2. Comparison of circulating EPCs and bone marrow EPCs by Flow Cytometry. (A) The number of circulating EPCs at different time
points after the major hepatectomy and partial I/R injury. (B) The number of EPCs in bone-marrow was detected by Flow Cytometry at four weeks
later after liver resection and I/R injury. Each group contained 16 rats, *P,0.05.
doi:10.1371/journal.pone.0032380.g002
Figure 3. Comparison of tumor angiogenesis in metastatic tumor nodules. (A) The expression of CD34 positive cells in intrahepatic and
lung metastatic tumor nodules. (B) Comparison of MVD in metastatic tumor nodules between treatment group and control group. Each group
contained 16 rats, *P,0.05.
doi:10.1371/journal.pone.0032380.g003
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apoptosis
Although with slight lymphocyte infiltration, hepatic lobular
architecture was well preserved after FTY720 treatment at 6 hours
after reperfusion (Figure 4A). The hepatocytes and portal tracts
showed normal morphological features. On the contrary, damage
of vascular endothelial cells together with patchy necrosis was
found around the portal tract in the control group at 6 h after
reperfusion (Figure 4A). Furthermore, FTY720 also prevented
hepatic apoptosis at 6 hours after reperfusion. Most of the
apoptotic liver cells were found in the control groups. However,
only a few apoptotic liver cells were found in the FTY720
treatment group. (Figure 4B, C).
FTY720 down-regulated the expression of CXCL10, VEGF,
CXCR3, and CXCR4
In order to explore the underlying mechanism of FTY720 on
suppression of circulating and bone marrow EPCs, the mRNA
and protein expression levels of CXCL10, VEGF, CXCR3, and
CXCR4 in liver tissue were compared between control group and
treatment group. FTY720 significantly down-regulated mRNA
and protein expression levels of CXCL10, VEGF, CXCR3, and
CXCR4 in liver tissue at 6 hours after major hepatectomy and
hepatic I/R injury compared to control group (Figure 5).
Discussion
Surgical stress injury such as hepatic I/R injury during liver
resection and liver transplantation rapidly enhances the number of
circulating EPCs [5–7]. EPCs play an important role in tumor
growth and metastasis [15–18,20]. Therefore, it is worthwhile to
study whether FTY720 suppresses liver tumor metastasis after
surgical resection by attenuating hepatic I/R injury and reducing
circulating EPCs.
In the present study, the effect of FTY720 on inhibition of liver
tumor metastasis after liver resection and I/R injury was first
shown in an orthotopic rat liver tumor model with local and
distant metastatic potentials. This model effectively mimicked
clinical liver tumor metastasis situation after liver surgery. In
addition to reduce the incidence of tumor metastasis, FTY720 also
significantly decreased the number and size of metastatic tumor
nodules at four weeks after liver resection and hepatic I/R injury.
In this study, our results showed that FTY720 significantly
reduced the number of circulating and bone marrow EPCs. The
phenomenon was consistent with the decrease of MVD in
metastatic tumor nodules. EPCs play important roles in tumor
vasculogenesis and tumor growth at early phase [10,15–17]. Our
results also confirmed that in both treatment and control groups,
the level of circulating EPCs was higher in the rats with metastasis
than without metastasis. Several studies in mice and human have
demonstrated that EPCs derived from bone marrow contribute to
tumor angiogenesis [15,16,31]. The extent of the contribution
depended on the tumor type, host and stage of tumorigenesis [32].
EPCs ablation can result in significant angiogenesis inhibition and
impaired tumor growth and metastasis [18,33,34]. Furthermore,
EPCs have major roles in tumor progression from micrometastases
to macrometastases [18]. Therefore, the effect of FTY720 on
inhibition of liver tumor metastasis was probably due to the
decrease of circulating EPCs level. Targeting circulating EPCs by
FTY720 treatment may effectively decrease tumor metastasis and
block metastasis progression from micrometastases to macrome-
tastases. However, the direct effects of FTY720 on the generation
of EPCs in bone marrow need to be further investigated.
To investigate the underlying mechanism of FTY720 on
suppression of circulating EPCs, the expression level of several
inflammatory chemokines and cytokines were analyzed. Our
studies indicated that FTY720 significantly attenuated hepatic I/R
injury and down-regulated intracellular mRNA and protein levels
of CXCL10, VEGF, CXCR4 and CXCR3. Several researches
Figure 4. Hepatic architecture and apoptosis at 6 hours after hepatectomy and hepatic I/R injury. (A) Hepatic architecture was examined
by H&E staining. (B) Hepatic apoptosis was detected by TUNEL staining. (C) Comparison of average apoptotic positive cells in 6 random fields (2006).
Each group contained 6 rats, *P,0.05.
doi:10.1371/journal.pone.0032380.g004
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resection and liver transplantation rapidly enhances the number of
circulating EPCs [5–7]. Mobilization and migration of EPCs is
also associated with elevated levels of angiogenic growth factors or
chemokines [8–10]. Recent studies demonstrate that VEGF,
CXCR3 and CXCR4 could play important roles in the migration
of circulating EPCs and enhanced vasculogenesis which subse-
quently contribute to neovascularization [8,35,36]. Vascular
endothelial growth inhibitor effectively inhibits mobilization and
differentiation of EPCs by suppression of endothelial cell-specific
gene expression in early-stage EPCs and induction of apoptosis in
late-stage EPCs [37]. Moreover, CXCL10 and VEGF also play
important role in tumor angiogenesis [38,39]. Our previous study
also showed that the downregulation of CXCL10 and VEGF by
adiponectin treatment could effectively reduce liver tumor growth
and metastasis [27]. Therefore, our result suggested suppression of
CXCL10, VEGF, CXCR3 and CXCR4 expression by FTY720
may be one of the mechanisms contributing to the reduction of
circulating EPCs and the decrease of neoangiogenesis. The specific
mechanisms of these molecules on FTY720-mediated suppressions
of circulating EPCs and neoangiogenesis need to be further
clarified.
In conclusion, FTY720 suppressed liver tumor metastasis after
hepatectomy and I/R injury through attenuating hepatic I/R
injury and reducing the numbers of circulating EPCs, suggesting
that it may be a promising candidate for potential adjuvant
therapies for treating liver cancer metastasis after liver surgery for
HCC patients.
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